
Oncology NEWS International
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
Don't Assume That Mental Symptoms Are Due to Opioids
MILAN, Italy--Opioids are not usually the cause of organic brain syndromes (most often delirium and hallucinations) in patients with chronic cancer pain, when other common medical conditions that develop in advanced cancer are considered,
MILAN, Italy--Opioids are not usually the cause of organic brainsyndromes (most often delirium and hallucinations) in patientswith chronic cancer pain, when other common medical conditionsthat develop in advanced cancer are considered, says Augusto Caraceni,MD, of the Pain Therapy and Palliative Care Division, NationalCancer Institute, Milan.
Dr. Caraceni and his colleagues reviewed 161 hospitalized patientswho received opioids for chronic cancer pain during a 14-monthperiod; 15 developed an organic brain syndrome. In four patients,opioids were found to be the only cause of the syndrome, but in11 cases, concomitant conditions could not be excluded as contributingto the etiology, and in some cases appeared to be the primarycause.
When opioids were clearly implicated as the cause of the organicbrain syndrome, opioid dosages were reduced to relieve mentalsymptoms, but patients were sometimes left with only partial painrelief, the researchers say (J Pain Symptom Management 9:527-533,1994).
The concomitant conditions included brain metastases, liver failure,renal failure, and hyponatremia (the three patients with hyponatremiaimproved when electrolytes were corrected and their morphine dosageswere reduced). Two patients were also receiving psychoactive drugs(amitriptyline and lorazepam), and both recovered when these drugswere discontinued.
In two patients with melanoma and bone metastases, use of IL-2or IL-2 and interferon appeared to be the primary cause of theirmental problems, and another patient was found to have hydrocephalusstemming from a metastatic brain lesion.
Dr. Caraceni concluded that in all cases of organic brain syndrome,"a very careful differential diagnosis is important to ruleout concomitant, and sometimes treatable, conditions."
His colleagues in the study were Drs. Cinzia Martini, Franco DeConno, and Vittorio Ventafridda, all with the National CancerInstitute, Milan.
Articles in this issue
about 31 years ago
First Results of Avicidin Trialsabout 31 years ago
Chemo Patients Often Develop Menstrual Irregularitiesabout 31 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicabout 31 years ago
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigationabout 31 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseaseabout 31 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialabout 31 years ago
Ultrasound Breast Screens Useful in Selected Womenabout 31 years ago
New Roles Forecast for Endocrine Therapyabout 31 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsabout 31 years ago
Anticancer Drugs From Zeneca in Regulatory Phase of DevelopmentRelated Content


TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer




















































